Evidence map›Paper›PMID 40874831›Full record

ArticleJMIR AI2025

Medical Expert Knowledge Meets AI to Enhance Symptom Checker Performance for Rare Disease Identification in Fabry Disease: Mixed Methods Study.

Anne Pankow, Nico Meißner-Bendzko, Jessica Kaufeld, Laura Fouquette, Fabienne Cotte, Stephen Gilbert, Ewelina Türk, Anibh Das, Christoph Terkamp, Gerhard-Rüdiger Burmester and 1 more

Abstract read
In one paragraph

Article in JMIR AI, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anne Pankow *Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID http://orcid.org/0009-0009-9665-5143
Nico Meißner-Bendzko *Ada Health GmbH, Berlin, Germany.ORCID http://orcid.org/0000-0003-0540-0823
Jessica KaufeldDepartment of Nephrology and Hypertension, Hannover Medical School, Carl-Neuberg-Strasse 1, Hannover, 30625, Germany, 49 511 532 3745.ORCID http://orcid.org/0000-0001-7718-3464
Laura FouquetteAda Health GmbH, Berlin, Germany.ORCID http://orcid.org/0000-0003-2105-2419
Fabienne CotteAda Health GmbH, Berlin, Germany.ORCID http://orcid.org/0000-0002-2898-422X
Stephen GilbertElse Kröner Fresenius Center for Digital Health, TU Dresden University of Technology, Dresden, Germany.ORCID http://orcid.org/0000-0002-1997-1689
Ewelina TürkAda Health GmbH, Berlin, Germany.ORCID http://orcid.org/0000-0003-3954-1210
Anibh DasDepartment of Paediatrics, Hannover Medical School, Hannover, Germany.ORCID http://orcid.org/0000-0001-5884-0852
Christoph TerkampDepartment of Gastroneterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.ORCID http://orcid.org/0009-0007-1489-1683
Gerhard-Rüdiger BurmesterDepartment of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0001-7518-1131
Annette Doris WagnerDepartment of Nephrology and Hypertension, Hannover Medical School, Carl-Neuberg-Strasse 1, Hannover, 30625, Germany, 49 511 532 3745.ORCID http://orcid.org/0000-0003-0640-8309

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Rare diseases, which affect millions of people worldwide, pose a major challenge, as it often takes years before an accurate diagnosis can be made. This delay results in substantial burdens for patients and health care systems, as misdiagnoses lead to inadequate treatment and increased costs. Artificial intelligence (AI)-powered symptom checkers (SCs) present an opportunity to flag rare diseases earlier in the diagnostic work-up. However, these tools are primarily based on published literature, which often contains incomplete data on rare diseases, resulting in compromised diagnostic accuracy. Integrating expert interview insights into SC models may enhance their performance, ensuring that rare diseases are considered sooner and diagnosed more accurately. Objective: The objectives of our study were to incorporate expert interview vignettes into AI-powered SCs, in addition to a traditional literature review, and to evaluate whether this novel approach improves diagnostic accuracy and user satisfaction for rare diseases, focusing on Fabry disease. Methods: This mixed methods prospective pilot study was conducted at Hannover Medical School, Germany. In the first phase, guided interviews were conducted with medical experts specialized in Fabry disease to create clinical vignettes that enriched the AI SC's Fabry disease model. In the second phase, adult patients with a confirmed diagnosis of Fabry disease used both the original and optimized SC versions in a randomized order. The versions, containing either the original or the optimized Fabry disease model, were evaluated based on diagnostic accuracy and user satisfaction, which were assessed through questionnaires. Results: Three medical experts with extensive experience in lysosomal storage disorder Fabry disease contributed to the creation of 5 clinical vignettes, which were integrated into the AI-powered SC. The study compared the original and optimized SC versions in 6 patients with Fabry disease. The optimized version improved diagnostic accuracy, with Fabry disease identified as the top suggestion in 33% (2/6) of cases, compared to 17% (1/6) with the original model. Additionally, overall user satisfaction was higher for the optimized version, with participants rating it more favorably in terms of symptom coverage and completeness. Conclusions: This study demonstrates that integrating expert-derived clinical vignettes into AI-powered SCs can improve diagnostic accuracy and user satisfaction, particularly for rare diseases. The optimized SC version, which incorporated these vignettes, showed improved performance in identifying Fabry disease as a top diagnostic suggestion and received higher user satisfaction ratings compared to the original version. To fully realize the potential of this approach, it is crucial to include vignettes representing atypical presentations and to conduct larger-scale studies to validate these findings.

Indexed as

AIappartificial intelligenceclinical databaseclinical vignettesFabry diseaseGaucher diseaseinterviewslysosomalmedical expertpatientPompe diseaserare diseasessymptom assessment

Identifiers

PMID40874831
PMCPMC12392689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.